A non-comparative multi-center randomized phase II study of nivolumab +/− ipilimumab for patients with metastatic sarcoma (Alliance A091401)
      QxMD      Google Scholar   
Citation:
Lancet Oncol vol 19 (3) 416-426
Year:
2018
Type:
Manuscript
Funding:
NCTN
Endpoint:
Primary
Analysis:
Primary
Data Sharing:
No-Data-Sharing
Status:
Presented/Published
Citation Status:
ppub
Note:
http://www.thelancet.com/pdfs/journals/lanonc/PIIS1470-2045(18)30006-8.pdf
Methodological:
No
Biospecimen:
No
SDC:
No
Book Volume:
7
Parents:
2678  
Children:
None
Program:
OGC
Primary Committee:
Experimental
Sec. Committees:
   
Pharmas:
 
Grants:
U10CA180821, U10CA180882, U10CA041287, U10CA045808, U10CA047642, U10CA077440, U10CA007968, U10CA077651, U10CA180791, U10CA180833, U10CA180836, UG1CA189858  
Corr. Author:
 
Authors:
                       
Networks:
COLUMBIA, IA018, LAPS-MN026, LAPS-MO011, LAPS-NY016, METROMIN, NC002   
Study
Alliance-A091401
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:
2
Keywords: